ASCO 2021 Archives - MPR

ASCO 2021

Venetoclax and ibrutinib are therapeutic agents for CLL.

Ibrutinib, Venetoclax Combination Shows Promise in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia

The following article features coverage from the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Click here to read more of MPR‘s conference coverage. Among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), fixed-duration, first-line treatment with ibrutinib and venetoclax appears to induce both deep and durable responses, according to research presented at…